Tests higher-dose adaptive radiation for chest small cell lung cancer
Tests adjusted, higher-dose chest radiation in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Key facts
- Where
- Edmonton, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Cross Cancer InstituteEdmonton, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AHS Cancer Control Alberta
- Trial code
- NCT04952480
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.Read full original descriptionShow less
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer (DARTS): A Prospective Phase II Trial Evaluating Local Control of Adaptive Dose-escalated Radiotherapy
The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.
Inclusion: Minimum 18 years of age; Biopsy proven, newly diagnosed, untreated SCLC; Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan and/or or PET-CT scan, CT head or MRI brain, or chest X-ray; Eligible for platinum doublet chemotherapy; Eligible for thoracic radiotherapy, which can also include ipsilateral supraclavicular lymph node disease; Capable of providing written, informed consent prior to participation in the study. Patient's legally authorized representative (LAR) may sign on behalf of the patient; Able and willing to comply with protocol rules and follow-up regimen; Performance status of ECOG 0-2; Pulmonary function tests showing FEV-1 >1.0L and DLCO > 50% predicted; Radiation-targetable intrathoracic disease.
Exclusion: Brain metastasis that has not been symptomatically stable on dexamethasone; Previous CNS or thoracic radiotherapy; Previous chemotherapy; Ineligibility for platinum doublet chemotherapy; Prior thoracic surgery; In LS-SCLC, patients that are not eligible for concurrent chemoradiotherapy; In ES-SCLC, patients that are not eligible for concurrent chemoradiotherapy under the experimental arm; No intrathoracic disease seen to target with radiation; Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes; Mixed histology disease; Active serious infection requiring therapy; 4 or more sites of extrathoracic disease, even if 2 or more of these are present in the same organ system; History of another primary malignancy other than cutaneous basal cell carcinoma unless disease-free for at least 5 years; Lack of intrathoracic disease or intrathoracic disease spread not feasible to treat with adaptive radiotherapy; CT contrast allergy or kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging); Life expectancy of less than 3 months; Pregnant or breast-feeding; Participant in development and conduct of the research study.